Endothelial to Mesenchymal Transition in Cardiovascular Disease
Icahn School of Medicine at Mount Sinai · Goethe University Frankfurt · +10 more institutions
Abstract
Endothelial to mesenchymal transition (EndMT) is a process whereby an endothelial cell undergoes a series of molecular events that lead to a change in phenotype toward a mesenchymal cell (e.g., myofibroblast, smooth muscle cell). EndMT plays a fundamental role during development, and mounting evidence indicates that EndMT is involved in adult cardiovascular diseases (CVDs), including atherosclerosis, pulmonary hypertension, valvular disease, and fibroelastosis. Therefore, the targeting of EndMT may hold therapeutic promise for treating CVD. However, the field faces a number of challenges, including the lack of a precise functional and molecular definition, a lack of understanding of the causative pathological…
Citation impact
- FWCI
- 46.97
- Percentile
- 100%
- References
- 153
Authors
7- JCJason C. KovacicCorresponding
Icahn School of Medicine at Mount Sinai
- SDStefanie Dimmeler
Goethe University Frankfurt, German Centre for Cardiovascular Research
- RPRichard P. Harvey
Victor Chang Cardiac Research Institute, St Vincent's Clinic, UNSW Sydney
- TFToren Finkel
University of Pittsburgh
- EAElena Aïkawa
Harvard University, Brigham and Women's Hospital
Topics & keywords
- Medicine
- Mesenchymal stem cell
- Disease
- Pathological
- Phenotype
- Pathology
- Genetics
- Biology
- Good health and well-being
Funding
- PRProgeria Research Foundation
- BHBritish Heart FoundationAward: RG/14/3/30706
- SCStem Cells AustraliaAward: SR110001002
- FLFondation LeducqAwards: 15 CVD 03, 13 CVD 01
- NNierstichtingAward: 15OP13
- NSNew South Wales Government
- NINational Institutes of HealthAwards: SR110001002, R01HL114805, R01HL136431, R01HL141917
- MRMedical Research Council
- NHNational Health and Medical Research CouncilAwards: 1074386, APP1118576